Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsHybridoma is a technique for animal cell fusion. In 1975, two British scientists found that the fused cells had the characteristics of parental cells and could be developed into simple cell lines by cloning.
Fig. 1 Antibody production by hybridoma technology.
According to this principle, a group of hybridoma cells that can infinitely produce antibodies can be obtained by fusing antigenic animal spleen cells (commonly used mouse B lymphocytes) with tumor cells that can reproduce infinitely (commonly used mouse myeloma cells). After single cloning, the cell population can continuously secrete a single specific monoclonal antibody (mAb). At present, the production of monoclonal antibodies using hybridoma technology has become one of the most valuable achievements in animal cell fusion.
Our custom hybridoma services:
Although hybridoma cells have great advantages in antibody production, this technique still has some shortcomings.
(1) Antibody quality fluctuation: antibody production depends on whether mice can produce target-specific antibodies, and the effect is affected by individual health status, immune status, and other factors. The consistency and repeatability of antibodies produced by different hybridoma cells are poor.
(2) Allergic reaction: this technique usually uses mouse cells for monoclonal antibody production, and animal-derived antibodies may cause allergic reactions in patients, limiting the use of hybridoma technology as clinical therapy.
(3) Loss of antibody specificity: although hybridoma cells can proliferate indefinitely and express antibodies, long-term cell proliferation and protein expression may lead to antibody gene mutation and invalidation of expressed antibodies.
(4) Cryopreservation loss: hybridoma cells usually need to be cryopreserved, and the cryopreservation process will also cause the disappearance of their monoclonal antibody specificity.
An effective method to solve the heterogeneity of hybridoma cell antibody quality and the limitations of sensitization and specificity loss is hybridoma cell antibody sequencing.
The sequencing of hybridoma cells is to reverse transcribe the RNA extracted from hybridoma cells to obtain cDNA, then amplify it with PCR, and then obtain the complete sequence information of the heavy and light chains of the antibody. Compared with monoclonal antibody amino acid sequencing, gene sequencing can more accurately identify amino acids that are difficult to distinguish in mass spectrometry identification, so it is more accurate.
The sequenced monoclonal antibodies will be preserved, transmitted, communicated, and identified in the form of base sequences. When needed, stable and large-scale antibody production is carried out by recombinant protein expression technology according to the sequence. In the follow-up process of antibody production, hybridoma cell culture and cell cryopreservation are no longer needed to avoid the loss of antibody specificity. In addition, the production of recombinant protein does not involve the process of immune response, which avoids human allergic reactions caused by animal-derived antibodies. The antibody can also be modified during the construction of the recombinant vector, such as antibody fragment expression, homotype replacement, chimeric antibody, and antibody humanization. In addition, the monoclonal antibody expressed by the recombinant protein has good consistency, high repeatability, and little quality difference between batches.
Fig. 2 Schematic representation of the approach for high-throughput sequencing of the Ig sequence repertoire. (Georgiou, G., 2014)
Our optional antibody sequencing services:
1. Provide complete gene sequence and related information: hybridoma sequencing service can provide complete gene sequence and related information on monoclonal antibodies to help better understand the characteristics and applications of antibodies.
2. Optimize the experimental scheme: by understanding the expression efficiency and stability of the antibody, we can optimize the expression and purification of the monoclonal antibody.
3. Improve the success rate of the experiment: understanding the characteristics and application of antibodies can help to better design the experimental scheme and improve the success rate of the experiment.
4. Reduce experimental costs: by understanding the characteristics and applications of antibodies, you can avoid wasting time and money on unnecessary experiments.
The base sequences obtained by hybridoma antibody sequencing can be permanently retained, prevent the loss of monoclonal antibody information, and can also be used to apply for protective patents. Secondly, a clear base sequence can assist researchers in the selection of target cell lines, so as to efficiently express recombinant monoclonal antibodies with higher purity through protein recombination technology. This technique can also be used to screen for mature affinity and further improve the affinity of monoclonal antibodies.
Hybridoma cell sequencing technology shows great advantages in the field of monoclonal antibody production. As an expert in antibody production and development, Creative Biolabs is committed to providing customers with high-quality hybridoma sequencing services. Creative Biolabs' technology platform can not only complete the sequencing of light chain, heavy chain, or full length, but also provide corresponding gene cloning, fluorescent protein tag modification, recombinant antibody expression, and even large-scale antibody production services according to customer requirements, saving economic and time costs for customers.
Complete sequence: For hybridoma cells, the antigenic lead peptide, variable region, and constant region can be sequenced, and the complete sequence is more helpful for antibody information preservation and recombinant expression.
Credible results: Thousands of mouse and rabbit antibodies have been sequenced in the past, and the sequences have been recombined and expressed to verify that the positive rate of ELISA is more than 99%.
Mature platform and one-stop service: There is an antibody recombinant expression and verification platform, which can provide antibody optimization services such as antibody humanization, codon optimization, and affinity maturation and can provide services such as recombinant antibody transient sample, antibody purification, and multi-platform verification.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
